Polycystic ovary syndrome: a simplified approach based on the evolving set of symptoms

similar regardless of whether urinary or recombinant gonadotrophins are used. In this article the author refers to the study of Gleicher et al. (2000), which makes no comparison between urinary and recombinant products, but instead questions whether ovulation induction in general should be replaced by IVF as a means of reducing the risk of higher order multiple pregnancy. To conclude, I feel that if we are to make progress in terms of how best to manage patients undergoing ART then we need to adopt an objective approach. Until evidence-based medicine can demonstrate differences between recombinant and urinary gonadotrophins, any attempt to promote recombinant and denigrate urinary gonadotrophins is as yet unsubstantiated.